Recombinant Newcastle Disease Virus as a Vaccine Vector
|
|
- Kathryn Adams
- 6 years ago
- Views:
Transcription
1 JOURNAL OF VIROLOGY, Dec. 2001, p Vol. 75, No X/01/$ DOI: /JVI Copyright 2001, American Society for Microbiology. All Rights Reserved. Recombinant Newcastle Disease Virus as a Vaccine Vector TAKAAKI NAKAYA, 1 JEROME CROS, 1 MAN-SEONG PARK, 1 YURIE NAKAYA, 1 HONGYONG ZHENG, 1 ANA SAGRERA, 2 ENRIQUE VILLAR, 2 ADOLFO GARCÍA-SASTRE, 1 * AND PETER PALESE 1 * Department of Microbiology, Mount Sinai School of Medicine, New York, New York 10029, 1 and Department of Biochemistry and Molecular Biology, University of Salamanca, Salamanca, Spain 2 Received 4 May 2001/Accepted 4 September 2001 A complete cdna clone of the Newcastle disease virus (NDV) vaccine strain Hitchner B1 was constructed, and infectious recombinant virus expressing an influenza virus hemagglutinin was generated by reverse genetics. The rescued virus induces a strong humoral antibody response against influenza virus and provides complete protection against a lethal dose of influenza virus challenge in mice, demonstrating the potential of recombinant NDV as a vaccine vector. * Corresponding author. Mailing address: Department of Microbiology, Mount Sinai School of Medicine, One Gustave Levy Pl., New York, NY Phone for Peter Palese: (212) Fax: (212) peter.palese@mssm.edu. Phone for Adolfo García- Sastre: (212) Fax: (212) adolfo.garcia -sastre@mssm.edu. Newcastle disease virus (NDV) is a member of the Rubulavirus genus in the Paramyxoviridae family and is categorized into three pathotypes depending on the severity of the disease that it causes in birds: lentogenic, mesogenic, or velogenic (1, 33). The ability to genetically engineer negative-strand RNA viruses has led to extraordinary advances in understanding their biology. The first reports of NDV rescue from cdna were published in 1999 (22, 28). Both groups used the lentogenic NDV strain LaSota. Recently, this strain was further attenuated by modifying the RNA editing site in the P gene, which resulted in low-level expression of the V protein (18). In addition, the generation of a chimeric recombinant NDV containing a hybrid HN gene with the N-terminal region derived from NDV and the external C-terminal region from avian paramyxovirus type 4 was reported (23). Finally, Krishnamurthy et al. (15) and Huang et al. (11) rescued recombinant NDVs (mesogenic strain Beaudette C and lentogenic strain LaSota, respectively) stably expressing the chloramphenicol acetyltransferase (CAT) reporter gene. An important application of reverse-genetic techniques is the generation of recombinant viruses for use as vaccine vectors (reviewed in references 4, 8, 19, 21, and 26). A number of recombinant negative-strand RNA viruses expressing foreign proteins have been constructed. Recombinant vesicular stomatitis viruses (VSVs) are able to express the human CD4 protein (32), the influenza virus hemagglutinin (HA) and neuraminidase (14, 25, 27), the respiratory syncytial virus G and F proteins (12), the human immunodeficiency virus Gag and Env proteins (10), and the bovine viral diarrhea virus E2 protein (9). Their efficacies as vaccine vectors have been studied (reviewed in reference 26). Among paramyxoviruses, several chimeric measles viruses and Sendai viruses expressing foreign genes have been constructed (29, 35, 38), and a rinderpest virus expressing an influenza virus HA protein has been described (37). The latter recombinant was shown to induce humoral immunity in vaccinated cattle (37). In this paper, a recombinant NDV expressing the HA protein of influenza A virus was generated from the full-length cdna of the avirulent strain Hitchner B1 (ATCC VR108), a widely used NDV live vaccine strain. The potential of the recombinant NDV as an effective vaccine vector was evaluated. Rescue of recombinant viruses from cloned cdnas. pndv/ B1, containing the full-length cdna of the Hitchner B1 strain was constructed (Fig. 1), and two additional restriction enzyme sites (SacII, nucleotides [nt] 1755 to 1760; and XbaI, nt 3163 to 3168) were created as genetic tag sequences. The complete genome (15,186 nt) of pndv/b1 was sequenced using a model ABI 3700 sequencer (Applied Biosystems). We chose the newly introduced XbaI site, located between the P and M genes to insert the CAT gene (24) or the HA gene of influenza A/WSN/33 virus (7). These constructs (pndv/b1-cat and pndv/b1-ha) should retain the normal ratio of NP to P expression, which appears to be critical for effective viral replication (2). The numbers of the inserted nucleotides in pndv/ B1-CAT and pndv/b1-ha were 696 and 1,752, respectively, maintaining the genome length as a multiple of 6 (3). To generate recombinant NDVs from pndv/b1, pndv/b1- CAT, and pndv/b1-ha, HEp-2 or A549 cells in a six-well plate were infected with MVA-T7 (kindly provided by B. Moss) at a multiplicity of infection of 1 and then transfected with each NDV full-length clone (1 g) together with the following expression plasmids: ptm1-np (nucleoprotein) at 0.4 g, ptm1-p (phosphoprotein) at 0.2 g, and ptm1-l (RNA-dependent RNA polymerase) at 0.2 g. After overnight incubation, the transfected cells were cocultured with chicken embryo fibroblasts (CEF) to amplify the produced virus and then incubated for an additional 2 to 3 days. The supernatants of transfected cells were injected into the allantoic cavities of 9- or 10-day-old embryonated chicken eggs. Three to four days later, allantoic fluids were harvested and virus growth was confirmed by hemagglutination assays followed by hemagglutination inhibition (HI) testing. Viral genomic RNAs were isolated from the rescued viruses (rndv/b1, rndv/b1-cat, and rndv/b1-ha) and the tagged restriction enzyme sites, and the presence of the inserted foreign genes was confirmed by reverse transcription-pcr restriction enzyme digestion analysis (data not shown)
2 VOL. 75, 2001 NOTES FIG. 1. Schematic representation of pndv/b1, pndv/b1-cat, and pndv/b1-ha cdna constructs. (A) pndv/b1 was generated by seven PCR fragments spanning the following nucleotide positions: F1, T7 promoter, nt 1755 (SacII); F2, nt 1 to 3321; F3, nt 1755 (SacII) to 6580; F4, nt 6151 to 10,210; F5, nt 7381 to 11,351; F6, nt 11,351 to 14,995; and F7, nt 14,701 to 15,186. These sequences were followed by the hepatitis delta virus (HDV) ribozyme and the T7 terminator. The cdna fragments were joined at shared restriction sites and assembled in plasmid psl1180 (Amersham Pharmacia Biotech). SacII and XbaI are shown in italics to indicate that they are genomic tag sequences. (B) The pndv/b1-cat and pndv/b1-ha constructs were made by inserting the CAT and influenza virus A/WSN/33 HA open reading frames (ORF), respectively, into the unique XbaI cloning site (nt 3163) located between the P and M genes of the pndv/b1 clone. The inserted gene contains the gene end (GE; 5 -TTAGAAAAAA-3 ), intercistronic nucleotide (T), and the gene start sequence (GS; 5 -ACGGGTAGAA-3 ). In addition, seven nucleotides (5 -CGCCACC-3 ) were inserted upstream of the initiation site to introduce an optimal Kozak sequence (13). In the case of pndv/b1-ha, the gene start sequence is followed by the 5 untranslated region (26 nt) of the HA gene. Downloaded from rndv/b1-ha virus stably expresses HA protein on the cell surface. The expression of HA protein was analyzed by infection of 35-mm-diameter dishes of confluent CEF cells with either rndv/b1 or rndv/b1-ha at a multiplicity of infection of 1. Cells were fixed at 1 and 2 days postinfection using 1% paraformaldehyde. NDV proteins and HA protein were visualized using a mouse anti-ndv polyclonal serum and a monoclonal antibody (2G9) against influenza virus HA, respectively, followed by incubation with peroxidase-conjugated anti-mouse immunoglobulins (Boehringer Mannheim). Extensive cytopathic effects and typical syncytia were observed in cells infected with rndv/b1 or rndv/b1-ha at 2 days postinfection (Fig. 2A, images a, b, c, e, f, and g) but not in mock-infected cells (Fig. 2A, images d and h). NDV infection was demonstrated by staining with an anti-ndv serum (Fig. 2A, images a, b, and c). In contrast, the HA-specific monoclonal antibody (2G9) reacted only with rndv/b1-ha-infected cells and not with rndv/b1- or mock-infected cells (Fig. 2A, images e, f, g, and h). These results suggested that the HA protein is efficiently expressed and transferred to the cell surfaces of rndv/ B1-HA-infected cells. A similar result was reported for recombinant VSV and rinderpest virus expressing the HA protein (14, 37). In addition, we demonstrated that the HA protein was stably expressed from rndv/b1-ha following 10 passages in embryonated eggs at a low multiplicity of infection (10 to 100 PFU/egg) (Fig. 2A, image g). The stable expression of a foreign gene was also confirmed using rndv/b1-cat. CAT expression was not changed after 10 passages in embryonated eggs at a low multiplicity of infection (data not shown). HA incorporation into virions. Previous studies showed that the HA protein expressed from recombinant VSV was efficiently incorporated into virions (14). On the other hand, recombinant rinderpest virus did not incorporate the expressed HA protein into particles (37). Thus, we wished to determine whether the HA protein was incorporated into the virions of the recombinant NDV. For this purpose, virions of rndv/b1- HA, rndv/b1, or influenza A/WSN/33 virus were purified and concentrated using a two-step centrifugation method (7,000 g for 30 min and 200, 000 g for 90 min over a 30% sucrose cushion). The total amount of protein in purified virus preparations was measured using a Bradford assay kit (Bio-Rad). Viral proteins were electrophoresed on a sodium dodecyl sulfate 10% polyacrylamide gel, followed by immunoblotting with anti-ha monoclonal antibodies (H15-A13, B-8, B-9, B-15, B-17, C-10, C-12, and E-10, kindly provided by W. Gerhard). The result showed that the amount of HA protein in the rndv/b1-ha virion was four- to eightfold lower than that in influenza A/WSN/33 virus, assuming that the same number of viral particles per microgram of viral proteins was present (Fig. 2B). The HA protein incorporated into rndv/b1-ha particles appeared to be cleaved, indicating that the HA protein was accessible to proteolytic enzymes. Virus growth kinetics and pathogenicity of rndv/b1-ha. Embryonated chicken eggs were inoculated with the parent on June 30, 2018 by guest
3 11870 NOTES J. VIROL. virus (wild-type NDV/B1 [wtndv/b1]), rndv/b1, rndv/b1cat, or rndv/b1-ha at 100 PFU per egg. Viral growth was analyzed at different time points after inoculation. A 50% tissue culture infective dose (TCID50) of each virus was determined by immunofluorescence assay. Ninety-six well plates of 80%-confluent CEF were infected with serial 10-fold dilutions of virus (four wells per dilution). Cells were incubated for 2 days and fixed with 2.5% formaldehyde containing 0.1% Triton X-100. Viral proteins were visualized using an anti-ndv rabbit serum followed by fluorescein isothiocyanate-conjugated antirabbit immunoglobulins (DAKO). wtndv/b1, rndv/b1, and rndv/b1-cat grew to similar titers (109 TCID50/ml), whereas the maximal viral titer achieved with rndv/b1-ha was approximately 20-fold lower (5 107 TCID50/ml) (Fig. 3). In order to test the virulence of rndv/b1-ha, the mean time of death in eggs was determined. Serial 10-fold dilutions of infectious allantoic fluid (10 6 to 10 8) of wtndv/b1, rndv/ B1, and rndv/b1-ha viruses were inoculated into each of five embryonated eggs and the mean time in hours for the minimal lethal dose to kill embryos was determined. Embryos inoculated with the wtndv/b1 and rndv/b1 viruses died within 6 days. The mean times of death of the wild-type virus and rndv/b1 were 108 and 113 h, respectively. In contrast, approximately 80% of embryos inoculated with rndv/b1-ha FIG. 2. Detection of the HA protein on infected cells and in purified virions. (A) rndv/b1- or rndv/b1-ha-infected cells were fixed with 1% paraformaldehyde at day 2 postinfection, and cells were used for immunostaining analysis. NDV protein expression on the surfaces of cells infected with rndv/b1 (a) or rndv/b1-ha passaged in eggs at a low multiplicity of infection three times (3rdP) (b) or 10 times (10thP) (c) was analyzed by using mouse anti-ndv serum. HA expression on the cell surfaces of rndv/b1 (e)- or rndv/b1-ha (f and g)-infected cells was analyzed by using anti-ha monoclonal antibody (2G9). Mock-infected cells were also analyzed as a control (d and h). (B) rndv/b1 and rndv/b1-ha were purified from allantoic fluids of infected embryonated chicken eggs. Influenza A/WSN/33 virus was purified from MDBK cell culture supernatants as a control. Serial twofold dilutions of A/WSN/33 viral proteins (1.5 to 0.19 g) and 3 g of rndv/b1-ha or rndv/b1 viral proteins were separated on a sodium dodecyl sulfate 10% polyacrylamide gel. The gel was transferred to a nitrocellulose membrane, and the HA protein was detected by chemiluminescence using a mixture of anti-ha monoclonal antibodies and an anti-mouse IgG peroxidase-labeled antibody (DAKO). HA0 and HA1 indicate uncleaved and cleaved HA protein, respectively.
4 VOL. 75, 2001 NOTES FIG. 3. Growth curves of wtndv/b1, rndv/b1, rndv/b1-cat, and rndv/b1-ha viruses in embryonated chicken eggs. Embryonated eggs were inoculated with 100 PFU of each virus, and allantoic fluids were harvested at different time points (24, 48, and 72 h postinoculation). Viral titers (TCID 50 ) in CEF were determined by immunofluorescence assay using anti-ndv rabbit serum and an anti-rabbit IgG fluorescein isothiocyanate-labeled antibody (DAKO). survived beyond 8 days postinoculation. Similar results were obtained if higher amounts of viruses (10 3 to 10 5 dilutions) were inoculated. These results indicate that rndv/b1-ha is attenuated in embryonated chicken eggs. Since NDV Hitchner B1 is routinely used to vaccinate poultry, rndv/b1 expressing an avian influenza virus HA could be used as a vaccine against avian influenza viruses as well as NDV. Immnunogenicity and pathogenicity of recombinant NDV in mice. We demonstrated that rndv/b1-ha efficiently expresses the HA protein on the surfaces of infected cells and that a significant amount of HA molecules is associated with the virus (Fig. 2). We next attempted to use this rndv/b1-ha as a vaccine vector to protect mice against challenge with influenza virus. Previous studies showed that recombinant VSV and recombinant rinderpest virus expressing the HA protein induced a humoral antibody responses in vivo (25, 27, 37). BALB/c mice were inoculated with rndv/b1-ha either intravenously or intraperitoneally at PFU per mouse. Phosphate-buffered saline (PBS) or the same amount of rndv/b1 was administered intravenously as a control. No weight loss was observed in mice inoculated with rndv/b1-ha or with rndv/b1 (data not shown). Although growth levels of these viruses in mice were not determined, the lack of weight loss suggests that rndv/b1 and rndv/b1-ha have little or no toxicity in mice. Mice inoculated with rndv/b1 or rndv/ B1-HA showed no measurable antibody response to either NDV or influenza virus 14 days after the initial inoculation (data not shown). One week after being given a booster injection (28 days after the initial inoculation), an antibody response against NDV was induced in mice inoculated with rndv/b1 or rndv/b1-ha by intravenous administration (Table 1). HI antibody titers against NDV in the two groups were similar (Table 1). Intraperitoneal administration of rndv/ B1-HA also induced a significant anti-ndv antibody response, but the HI titers were lower than those after the intravenous administration. As expected, specific anti-influenza virus antibody was detected only in mice inoculated with rndv/b1-ha. Intravenous administration induced higher titers of antibody to influenza virus HA than intraperitoneal administration (Table 1). Efficacy of recombinant NDV in generating protective immunity. On day 35 after the initial inoculation (2 weeks after Group TABLE 1. Protection of mice immunized with rndv/b1-ha following challenge with influenza A/WSN/33 virus Immunization HA antibody titer a with: No. of survivors (n 5) after: Virus Dose (PFU) (10 7 ) Administration Anti-NDV Anti-influenza A/WSN virus Immunization A rndv/b1 3 Intravenous 1:480 ND c 5 0 B rndv/b1-ha 3 Intravenous 1:360 1: C rndv/b1-ha 3 Intraperitoneal 1:140 1: D PBS 0 Intravenous ND ND 5 0 a Sera were collected on day 28 (1 week after the booster injection) after the first inoculation. Values are averages of HA antibody titers of five mice. b Mice were challenged with 10 5 PFU (100 LD 50 )ofinfluenza A/WSN/33 virus on day 35 after the first inoculation. c ND, not detectable. Challenge b
5 11872 NOTES J. VIROL. FIG. 4. Average body weights of vaccinated mice after influenza virus challenge. Vaccinated mice were challenged with a lethal dose (100 LD 50 ) of influenza A/WSN/33 virus on day 35 (2 weeks after the booster injection). Relative average daily body weights (percentages) of mice vaccinated with rndv/b1-ha intravenously (i.v.) (f) or intraperitoneally (i.p.) (Œ), with rndv/b1 intravenously ( ), or with PBS (F) are shown. The vaccinating dose was PFU/ml in all cases. The error bars indicate 0.5 times the standard deviation. the booster injection), mice were challenged with 10 5 PFU (100 50% lethal doses [LD 50 ]) of influenza A/WSN/33 virus by intranasal administration. As shown in Fig. 4 and Table 1, rndv/b1-ha-immunized mice were protected against a lethal dose of influenza virus. In the case of intraperitoneal administration, although detectable weight loss was observed at first, mice fully recovered within 10 days (Fig. 4). In addition, no changes in physical activity and fur appearance were observed after influenza virus challenge in any of the vaccinated mice. In contrast, control mice inoculated with rndv/b1 or PBS were not protected and died within 7 days of the influenza virus challenge (Fig. 4 and Table 1). Previous studies (6, 36) found that protection is related to HA antibody induction, and our investigation is consistent with these findings (Table 1). Little is known about the replication of lentogenic NDV in mice. Analysis of the growth kinetics and tissue distribution of NDV/B1 in mammalian animals remains to be done. However, it has been demonstrated that virulent NDV replicates in mice (17). Also, certain NDV strains (including pathogenic and avirulent strains) have been shown to possess oncolytic activity (reviewed in reference 34) and, most importantly, it has been reported that NDV can infect humans without inducing severe symptoms (5, 20, 30). Clinical trials using NDV as an antitumor agent have shown encouraging preliminary results for patients with a variety of cancers, and phase III trials are beginning in Europe (20). These results indicate the potential of using recombinant NDVs in humans. Recombinant NDVs expressing components of other human pathogens might be able to induce, without severe side effects, a protective immune response to these agents. A recombinant NDV-based vaccine against human immunodeficiency virus may thus be envisioned. In addition, NDV-infected cells have been shown to produce cytokines such as interferons and tumor necrosis factor, stimulating immune responses (16, 31, 34). This immune response-stimulatory activity of NDV may be the reason for the finding that patients developed a highly immunogenic response to their own tumor following administration of X-rayirradiated NDV-infected autologous tumor cells (reviewed in reference 30). In conclusion, recombinant NDV expressing the influenza virus HA protein was generated from cdna of the Hitchner B1 vaccine strain by reverse genetics. This recombinant virus stably expressed the HA protein in infected cells and induced a protective immune response against influenza virus in mice. Our studies suggest that recombinant NDV may be a safe and effective vaccine vector for possible use in mammalian and avian species. Nucleotide sequence accession number. The complete genome (15,186 nt) of pndv/b1 was submitted to GenBank under accession number AF This work was partially supported by grants to A.G.-S. from the National Institutes of Health, by grants to P.P. from the National Institutes of Health, and by a grant to E.V. from the Direccion General de Ensenanza Superior of Spain (DGES PM97/0160). Y.N. was supported by an Uehara Memorial Bio-Medical Research Foundation fellowship. A mixture of monoclonal antibodies to the influenza A/WSN/33 virus HA was kindly provided by Walter Gerhard. ptm1 and MVA-T7 were kindly provided by Bernard Moss.
6 VOL. 75, 2001 NOTES REFERENCES 1. Alexander, D. J Newcastle disease, Newcastle disease virus an avian paramyxovirus, p Kluwer Academic Publishers, Dordrecht, The Netherlands. 2. Baron, M. D., M. Foster-Cuevas, J. Baron, and T. Barrett Expression in cattle of epitopes of a heterologous virus using a recombinant rinderpest virus. J. Gen. Virol. 80: Calain, P., and L. Roux The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J. Virol. 67: Conzelmann, K. K Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes. Annu. Rev. Genet. 32: Csatary, L. K., S. Eckhardt, I. Bukosza, F. Czegledi, C. Fenyvesi, P. Gergely, B. Bodey, and C. M. Csatary Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect. Prev. 17: Deck, R. R., C. M. DeWitt, J. J. Donnelly, M. A. Liu, and J. B. Ulmer Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine. Vaccine 15: Enami, M., and P. Palese High-efficiency formation of influenza virus transfectants. J. Virol. 65: García-Sastre, A Negative-strand RNA viruses: applications to biotechnology. Trends Biotechnol. 16: Grigera, P. R., M. P. Marzocca, A. V. Capozzo, L. Buonocore, R. O. Donis, and J. K. Rose Presence of bovine viral diarrhea virus (BVDV) E2 glycoprotein in VSV recombinant particles and induction of neutralizing BVDV antibodies in mice. Virus Res. 69: Haglund, K., J. Forman, H. G. Krausslich, and J. K. Rose Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 268: Huang, Z., S. Krishnamurthy, A. Panda, and S. K. Samal High-level expression of a foreign gene from the most 3 -proximal locus of a recombinant Newcastle disease virus. J. Gen. Virol. 82: Kahn, J. S., M. J. Schnell, L. Buonocore, and J. K. Rose Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology 254: Kozak, M At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J. Mol. Biol. 196: Kretzschmar, E., L. Buonocore, M. J. Schnell, and J. K. Rose Highefficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J. Virol. 71: Krishnamurthy, S., Z. Huang, and S. K. Samal Recovery of a virulent strain of Newcastle disease virus from cloned cdna: expression of a foreign gene results in growth retardation and attenuation. Virology 278: Le Bon, A., G. Schiavoni, G. D Agostino, I. Gresser, F. Belardelli, and D. F. Tough Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14: Lorence, R. M., B. B. Katubig, K. W. Reichard, H. M. Reyes, A. Phuangsab, M. D. Sassetti, R. J. Walter, and M. E. Peeples Complete regression of human fibrosarcoma xenograft after local Newcastle disease virus therapy. Cancer Res. 54: Mebatsion, T., S. Verstegen, L. T. de Vaan, A. Römer-Oberdörfer, and C. C. Schrier A recombinant Newcastle disease virus with low-level V protein expression is immunogenic and lacks pathogenicity for chicken embryos. J. Virol. 75: Nagai, Y., and A. Kato Paramyxovirus reverse genetics is coming of age. Microbiol. Immunol. 43: Nelson, N. J Scientific interest in Newcastle disease virus is reviving. J. Natl. Cancer Inst. 91: Palese, P., H. Zheng, O. G. Engelhardt, S. Pleschka, and A. García-Sastre Negative-strand RNA viruses: genetic engineering and applications. Proc. Natl. Acad. Sci. USA 93: Peeters, B. P. H., O. S. de Leeuw, G. Koch, and A. L. J. Gielkens Rescue of Newcastle disease virus from cloned cdna: evidence that cleavability of the fusion protein is a major determinant for virulence. J. Virol. 73: Peeters, B. P. H., O. S. de Leeuw, I. Verstegan, G. Koch, and A. L. J. Gielkens Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals. Vaccine 19: Pleschka, S., R. Jaskunas, O. G. Engelhardt, T. Zurcher, P. Palese, and A. García-Sastre A plasmid-based reverse genetics system for influenza A virus. J. Virol. 70: Roberts, A., E. Kretzschmar, A. S. Perkins, J. Forman, R. Price, L. Buonocore, Y. Kawaoka, and J. K. Rose Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J. Virol. 72: Roberts, A., and J. K. Rose Recovery of negative-strand RNA viruses from plasmid DNAs: a positive approach revitalizes a negative field. Virology 247: Roberts, A., L. Buonocore, R. Price, J. Forman, and J. K. Rose Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol. 73: Römer-Oberdörfer, A., E. Mundt, T. Mebatsion, U. Buchholz, and T. C. Mettenleiter Generation of recombinant lentogenic Newcastle disease virus from cdna. J. Gen. Virol. 80: Sakai, Y., K. Kiyotani, M. Fukumura, M. Asakawa, A. Kato, T. Shioda, T. Yoshida, A. Tanaka, M. Hasegawa, and Y. Nagai Accommodation of foreign genes into the Sendai virus genome: sizes of inserted genes and viral replication. FEBS Lett. 456: Schirrmacher, V., T. Ahlert, T. Probstle, H. H. Steiner, C. Herold-Mende, R. Gerhards, E. Hagmuller, and H. H. Steiner Immunization with virusmodified tumor cells. Semin. Oncol. 25: Schirrmacher, V., C. Haas, R. Bonifer, T. Ahlert, R. Gerhards, and C. Ertel Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther. 6: Schnell, M. J., J. E. Johnson, L. Buonocore, and J. K. Rose Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 90: Seal, B. S., D. J. King, and H. S. Sellers The avian response to Newcastle disease virus. Dev. Comp. Immunol. 24: Sinkovics, J. G., and J. C. Horvath Newcastle disease virus (NDV): brief history of its oncolytic strains. J. Clin. Virol. 16: Spielhofer, P., T. Bachi, T. Fehr, G. Christiansen, R. Cattaneo, K. Kaelin, M. A. Billeter, and H. Y. Naim Chimeric measles viruses with a foreign envelope. J. Virol. 72: Suarez, D. L., and S. Scultz-Cherry Immunology of avian influenza virus: a review. Dev. Comp. Immunol. 24: Walsh, E. P., M. D. Baron, L. F. Rennie, P. Monaghan, J. Anderson, and T. Barrett Recombinant rinderpest vaccines expressing membrane-anchored proteins as genetic markers: evidence of exclusion of marker protein from the virus envelope. J. Virol. 74: Wang, Z., L. Hangartner, T. I. Cornu, L. R. Martin, A. Zuniga, M. A. Billeter, and H. Y. Naim Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine 19:
Shin-Hee Kim, Yongqi Yan, and Siba K. Samal*
JOURNAL OF VIROLOGY, Oct. 2009, p. 10250 10255 Vol. 83, No. 19 0022-538X/09/$08.00 0 doi:10.1128/jvi.01038-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Role of the Cytoplasmic
More informationRecombinant Newcastle Disease Virus as a Vaccine Vector
Recombinant Newcastle Disease Virus as a Vaccine Vector Z. Huang, S. Elankumaran, A. Panda, and S. K. Samal 1 Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, 8075 Greenmead
More informationMINIREVIEW. Recovery of Negative-Strand RNA Viruses from Plasmid DNAs: A Positive Approach Revitalizes a Negative Field
VIROLOGY 247, 1 6 (1998) ARTICLE NO. VY989250 MINIREVIEW Recovery of Negative-Strand RNA Viruses from Plasmid DNAs: A Positive Approach Revitalizes a Negative Field Anjeanette Roberts and John K. Rose
More informationExpression of Transgenes from Newcastle Disease Virus with a Segmented Genome
JOURNAL OF VIROLOGY, Mar. 2008, p. 2692 2698 Vol. 82, No. 6 0022-538X/08/$08.00 0 doi:10.1128/jvi.02341-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Expression of Transgenes
More informationBlocking Interhost Transmission of Influenza Virus by Vaccination in the Guinea Pig Model
JOURNAL OF VIROLOGY, Apr. 2009, p. 2803 2818 Vol. 83, No. 7 0022-538X/09/$08.00 0 doi:10.1128/jvi.02424-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Blocking Interhost Transmission
More informationPlasmid-Driven Formation of Influenza Virus-Like Particles
JOURNAL OF VIROLOGY, Jan. 2000, p. 547 551 Vol. 74, No. 1 0022-538X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Plasmid-Driven Formation of Influenza Virus-Like
More informationNewcastle Disease Virus V Protein Is a Determinant of Host Range Restriction
JOURNAL OF VIROLOGY, Sept. 2003, p. 9522 9532 Vol. 77, No. 17 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.17.9522 9532.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Newcastle
More informationhemagglutinin and the neuraminidase genes (RNA/recombinant viruses/polyacrylamide gel electrophoresis/genetics)
Proc. Natl. Acad. Sci. USA Vol. 73, No. 6, pp. 242-246, June 976 Microbiology Mapping of the influenza virus genome: Identification of the hemagglutinin and the neuraminidase genes (RNA/recombinant viruses/polyacrylamide
More informationReceived 6 May 2011/Accepted 4 August 2011
JOURNAL OF VIROLOGY, Oct. 2011, p. 10529 10541 Vol. 85, No. 20 0022-538X/11/$12.00 doi:10.1128/jvi.05050-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Newcastle Disease Virus
More informationABSTRACT PROTEIN IN NEWCASTLE DISEASE VIRUS. Aruna Panda, Doctor of Philosophy, Professor College of Veterinary Medicine
ABSTRACT Title of Dissertation: ROLE OF HEMAGGLUTININ-NEURAMINIDASE PROTEIN IN NEWCASTLE DISEASE VIRUS PATHOGENESIS Aruna Panda, Doctor of Philosophy, 2003 Dissertation directed by: Dr. Siba K. Samal Professor
More informationInfluenza or flu is a
Clinical and Research Area Infectious Diseases Influenza Virus Types A and B Influenza or flu is a respiratory illness that is caused by influenza viruses. Influenza viruses type A and type B cause seasonal
More informationC E E Z A D. Rational Development of Influenza Vaccines: NDV-based influenza vaccines for poultry and livestock
C E E Z A D Center of Excellence for Emerging and Zoonotic Animal Diseases A Department of Homeland Security Center of Excellence Rational Development of Influenza Vaccines: NDV-based influenza vaccines
More informationThe humoral immune responses to IBV proteins.
The humoral immune responses to IBV proteins. E. Dan Heller and Rosa Meir The Hebrew University of Jerusalem, Israel COST FA1207 meeting WG2 + WG3, Budapest, Jan. 2015 1 IBV encodes four major structural
More informationContribution of the length of the HN protein and the sequence of the F protein cleavage site to Newcastle disease virus pathogenicity
Journal of General Virology (2003), 84, 3121 3129 DOI 10.1099/vir.0.19416-0 Contribution of the length of the HN protein and the sequence of the F protein cleavage site to Newcastle disease virus pathogenicity
More informationMultiplication of the V4 strain of Newcastle disease virus in Madin Derby bovine kidney cells
Onderstepoort Journal of Veterinary Research, 69:201-206 (2002) Multiplication of the V4 strain of Newcastle disease virus in Madin Derby bovine kidney cells M. SAHLE1*, W.G. BURGESS2 and A. KIDANEMARIAM1
More informationNewcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza
Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza Jutta Veits*, Dorothee Wiesner*, Walter Fuchs*, Bernd Hoffmann, Harald Granzow,
More informationNegative-strand RNA viruses: Genetic engineering and applications
Proc. Natl. Acad. Sci. USA Vol. 93, pp. 11354-11358, October 1996 Colloquium Paper This paper was presented at a colloquium entitled "Genetic Engineering of Viruses and of Virus Vectors," organized by
More informationTechnology Overview. Summary
Live Attenuated Influenza Vaccines with Altered NS1 Technology Overview Summary Transformative Technology: Live attenuated influenza vaccines (LAIVs) with precise, genetically stable truncations of the
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION Viral vector vaccines expressing nucleoprotein and phosphoprotein genes of avian bornaviruses ameliorate homologous challenge infections in cockatiels and common canaries Marita
More informationNewcastle Disease Virus V Protein Is Associated with Viral Pathogenesis and Functions as an Alpha Interferon Antagonist
JOURNAL OF VIROLOGY, Aug. 2003, p. 8676 8685 Vol. 77, No. 16 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.16.8676 8685.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Newcastle
More informationResearch Update: Avian Disease & Oncology Lab (ADOL) and SEPRL Endemic Poultry Virus Diseases (EPVD)
Research Update: Avian Disease & Oncology Lab (ADOL) and SEPRL Endemic Poultry Virus Diseases (EPVD) John Dunn, Hans Cheng, Mohammad Heidari, Huanmin Zhang, Taejoong Kim, Stephen Spatz, Qingzhong Yu USDA-ARS-USPNRC
More informationVIROLOGY. Engineering Viral Genomes: Retrovirus Vectors
VIROLOGY Engineering Viral Genomes: Retrovirus Vectors Viral vectors Retrovirus replicative cycle Most mammalian retroviruses use trna PRO, trna Lys3, trna Lys1,2 The partially unfolded trna is annealed
More informationViral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP
Viral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP 1 Learning Objectives Recognize hazards associated with viral vectors in research and animal
More informationHeat-killed Lactobacillus casei
Heat-killed Lactobacillus casei confers broad protection against influenza A virus primary infection and develops heterosubtypic immunity against future secondary infection Yu-Jin Jung, Young-Tae Lee,
More informationEngineered viral vaccine constructs with dual specificity: Avian influenza and Newcastle disease
Engineered viral vaccine constructs with dual specificity: Avian influenza and Newcastle disease Man-Seong Park*, John Steel*, Adolfo García-Sastre*, David Swayne, and Peter Palese* *Department of Microbiology,
More informationAbstract. Introduction
Generation by Reverse Genetics of an Effective, Stable, Live-Attenuated Newcastle Disease Virus Vaccine Based on a Currently Circulating, Highly Virulent Indonesian Strain Sa Xiao 1, Baibaswata Nayak 1,
More informationLive Bivalent Vaccine for Parainfluenza and Influenza Virus Infections
JOURNAL OF VIROLOGY, June 2005, p. 6674 6679 Vol. 79, No. 11 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.11.6674 6679.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Live Bivalent
More informationApplication of Reverse Genetics to Influenza Vaccine Development
NIAID Application of Reverse Genetics to Influenza Vaccine Development Kanta Subbarao Laboratory of Infectious Diseases NIAID, NIH Licensed Vaccines for Influenza Principle: Induction of a protective
More informationCristina Cassetti, Ph.D.
NIAID Extramural Research Update: Recombinant Influenza Viruses and Biosafety Cristina Cassetti, Ph.D. Influenza Program Officer Division of Microbiology and Infectious Diseases NIAID Influenza virus DMID
More informationLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, 7 Center Drive MSC 0720, Bethesda, MD
Proc. Natl. Acad. Sci. USA Vol. 96, pp. 11259 11264, September 1999 Biochemistry The M2 2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication
More informationGene Vaccine Dr. Sina Soleimani
Gene Vaccine Dr. Sina Soleimani Human Viral Vaccines Quality Control Laboratory (HVVQC) Titles 1. A short Introduction of Vaccine History 2. First Lineage of Vaccines 3. Second Lineage of Vaccines 3. New
More informationNewcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and
JVI Accepts, published online ahead of print on 1 June 0 J. Virol. doi:./jvi.001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. 1 Newcastle
More informationA Recombinant Newcastle Disease Virus (NDV) Expressing VP2 Protein of Infectious Bursal Disease Virus (IBDV) Protects against NDV and IBDV
JOURNAL OF VIROLOGY, Sept. 2004, p. 10054 10063 Vol. 78, No. 18 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.18.10054 10063.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. A Recombinant
More informationJudith G. Alamares, Jianrong Li, and Ronald M. Iorio*
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2005, p. 4229 4233 Vol. 43, No. 8 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.8.4229 4233.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationhowever, and the present communication is concerned with some of
THE AGGLUTINATION OF HUMAN ERYTHROCYTES MODIFIED BY TREATMENT WITH NEWCASTLE DISEASE AND INFLUENZA VIRUS' ALFRED L. FLORMAN' Pediatric Service and Division of Bacteriology, The Mount Sinai Hospital, New
More informationMINIREVIEW. Reverse Genetics of Influenza Virus
Virology 287, 243 250 (2001) doi:10.1006/viro.2001.1008, available online at http://www.idealibrary.com on MINIREVIEW Reverse Genetics of Influenza Virus Gabriele Neumann* and Yoshihiro Kawaoka*,,1 *Department
More informationJOURNAL OF VIROLOGY, Nov. 2000, p Vol. 74, No. 21. Copyright 2000, American Society for Microbiology. All Rights Reserved.
JOURNAL OF VIROLOGY, Nov. 2000, p. 10165 10175 Vol. 74, No. 21 0022-538X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Recombinant Rinderpest Vaccines Expressing Membrane-
More informationRecombinant influenza viruses as delivery vectors for hepatis B virus epitopes
Original article CLINICAL EXPERIMENTAL VACCINE RESEARCH Recombinant influenza viruses as delivery vectors for hepatis B virus epitopes Clin Exp Vaccine Res 2012;1:77-82 http://dx.doi.org/10.7774/cevr.2012.1.1.77
More informationRecommended laboratory tests to identify influenza A/H5 virus in specimens from patients with an influenza-like illness
World Health Organization Recommended laboratory tests to identify influenza A/H5 virus in specimens from patients with an influenza-like illness General information Highly pathogenic avian influenza (HPAI)
More informationViral vaccines. Lec. 3 أ.د.فائزة عبد هللا مخلص
Lec. 3 أ.د.فائزة عبد هللا مخلص Viral vaccines 0bjectives 1-Define active immunity. 2-Describe the methods used for the preparation of attenuated live & killed virus vaccines. 3- Comparison of Characteristics
More informationReassortment of influenza A virus genes linked to PB1 polymerase gene
International Congress Series 1263 (2004) 714 718 Reassortment of influenza A virus genes linked to PB1 polymerase gene Jean C. Downie* www.ics-elsevier.com Centre for Infectious Diseases and Microbiology,
More informationGeneration and characterization of a recombinant Newcastle disease virus expressing the red fluorescent protein for use in co-infection studies
Li et al. Virology Journal 2012, 9:227 RESEARCH Open Access Generation and characterization of a recombinant Newcastle disease virus expressing the red fluorescent protein for use in co-infection studies
More informationEtiology. Paramyxovirus type 1 = Newcastle disease.
Newcastle Disease Many strains of similar virus cause signs ranging from mild respiratory signs (pneumotropic) with low mortality to severe neurological (neurotropic) and/or visceral lesions (viscerotropic)
More informationTemperature-Sensitive Mutants Isolated from Hamster and
JOURNAL OF VIROLOGY, Nov. 1975, p. 1332-1336 Copyright i 1975 American Society for Microbiology Vol. 16, No. 5 Printed in U.S.A. Temperature-Sensitive Mutants Isolated from Hamster and Canine Cell Lines
More informationDeveloping a safe and effective vaccine against human immunodeficiency
RESEARCH ARTICLE crossmark Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against
More informationRabies virus-like particles expressed in HEK293 cells
Engineering Conferences International ECI Digital Archives Vaccine Technology IV Proceedings Spring 5-21-2012 Rabies virus-like particles expressed in HEK293 cells Diego Fontana Cell Culture Laboratory
More informationSupporting Information
Supporting Information Valkenburg et al. 10.1073/pnas.1403684111 SI Materials and Methods ELISA and Microneutralization. Sera were treated with Receptor Destroying Enzyme II (RDE II, Accurate) before ELISA
More informationSupplementary information. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins
Supplementary information inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins Takuya Tada, Yanzhao Zhang, Takayoshi Koyama, Minoru Tobiume, Yasuko Tsunetsugu-Yokota, Shoji
More informationReceived 11 November 1997/Accepted 2 March 1998
JOURNAL OF VIROLOGY, June 1998, p. 4704 4711 Vol. 72, No. 6 0022-538X/98/$04.00 0 Copyright 1998, American Society for Microbiology Vaccination with a Recombinant Vesicular Stomatitis Virus Expressing
More informationG. W. WOOD J. C. MUSKETT and D. H. THORNTON MAFF, Central Veterinary Laboratory, New Haw, Weybridge, Surrey, U.K.
J. Comp. Path. 1986 vol. 96 OBSERVATIONS ON THE ABILITY OF AVIAN REOVIRUS VACCINMATION OF HENS TO PROTECT THEIR PROGENY AGAINST THE EFFECTS OF CHALLENGE WITH HOMOLOGOUS AND HETEROLOGOUS STRAINS By G. W.
More informationExpression of HIV-1 Gag and Env Genes Using the Vesicular Stomatitis Virus Vector System
Western University Scholarship@Western 2015 Undergraduate Awards The Undergraduate Awards 2015 Expression of HIV-1 Gag and Env Genes Using the Vesicular Stomatitis Virus Vector System Justine Baek Western
More information(;[rowth Charaeteristies of Influenza Virus Type C in Avian Hosts
Archives of Virology 58, 349--353 (1978) Archives of Virology by Springer-Verlag 1978 (;[rowth Charaeteristies of Influena Virus Type C in Avian Hosts Brief Report By M ~R A~N D. AUSTIn, A. S. MONTO, and
More informationThe M, F and HN genes of genotype VIId Newcastle disease virus are associated with the severe pathological changes in the spleen of chickens
Kai et al. Virology Journal (2015) 12:133 DOI 10.1186/s12985-015-0366-5 RESEARCH Open Access The M, F and HN genes of genotype VIId Newcastle disease virus are associated with the severe pathological changes
More informationPERSISTENT INFECTIONS WITH HUMAN PARAINFLUENZAVIRUS TYPE 3 IN TWO CELL LINES
71 PERSISTENT INFECTIONS WITH HUMAN PARAINFLUENZAVIRUS TYPE 3 IN TWO CELL LINES Harold G. Jensen, Alan J. Parkinson, and L. Vernon Scott* Department of Microbiology & Immunology, University of Oklahoma
More informationInfluenza vaccines: present and future
PERSPECTIVE SERIES The future of vaccine design Peter Palese and Adolfo García-Sastre, Series Editors Influenza vaccines: present and future Peter Palese and Adolfo García-Sastre Department of Microbiology,
More informationReceived 15 July 2006/Accepted 9 October 2006
JOURNAL OF VIROLOGY, Jan. 2007, p. 150 158 Vol. 81, No. 1 0022-538X/07/$08.00 0 doi:10.1128/jvi.01514-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Newcastle Disease Virus-Based
More informationIMMUNOGENICITY OF FORMALDYDE INACTIVATED NEWCASTLE DISEASE VIRUS FIELD ISOLATE IN MATERNAL ANTIBODY FREE CHICKENS
IMMUNOGENICITY OF FORMALDYDE INACTIVATED NEWCASTLE DISEASE VIRUS FIELD ISOLATE IN MATERNAL ANTIBODY FREE CHICKENS Anak Agung Ayu Mirah Adi 1 *, IGusti Agung Arta Putra 2, Nyoman Mantik Astawa 3, I Made
More informationResearch Article Biological Pathotyping of Newcastle Disease Viruses in Sudan
, Article ID 209357, 4 pages http://dx.doi.org/10.1155/2014/209357 Research Article Biological Pathotyping of Newcastle Disease Viruses in Sudan 2008 2013 Egbal Sidahmed Abdelrahim Bilal, Iman Mohammed
More informationPersistent Infection of MDCK Cells by Influenza C Virus: Initiation and Characterization
J. gen. Virol. (199), 70, 341-345. Printed in Great Britain 341 Key words: influenza C virus/interferon/persistent infection Persistent Infection of MDCK Cells by Influenza C Virus: Initiation and Characterization
More informationBiotechnology-Based Vaccines. Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
Biotechnology-Based Vaccines Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Objectives of this lecture By the end of this lecture you will be able to: 1.
More informationCancer immunotherapy with oncolytic viruses: more than just lysis
Cancer immunotherapy with oncolytic viruses: more than just lysis Dmitriy Zamarin MD PhD Assistant Attending, Immune Therapeutics Center Memorial Sloan-Kettering Cancer Center New York, NY BCAN Think Tank
More informationSupplemental Information Dose Response Parameters for Gain of Function Pathogens
Supplemental Information Dose Response Parameters for Gain of Function Pathogens Infection Dose-Response To quantify the likelihood of an individual or animal becoming infected from exposure to virus,
More informationObjective 3. Develop new and improved diagnostic tools, vaccines, and novel management approaches
Objective 3. Develop new and improved diagnostic tools, vaccines, and novel management approaches Development of novel nanoparticle-base vaccines for infectious bronchitis PI, Mazhar I. Khan; CoPI, Peter
More informationThe use of nonhuman primates in biomedical research has led to the isolation of many
JVI Accepts, published online ahead of print on 29 September 2010 J. Virol. doi:10.1128/jvi.01928-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationUnité de Génétique Moléculaire des Virus Respiratoires, URA 1966 CNRS, Institut Pasteur, 25 rue du Dr. Roux, PARIS Cedex 15, France
Virology 345 (2006) 73 87 www.elsevier.com/locate/yviro Recombinant influenza A viruses harboring optimized dicistronic NA segment with an extended native 5V terminal sequence: Induction of heterospecific
More informationnumbe r Done by Corrected by Doctor
numbe r 5 Done by Mustafa Khader Corrected by Mahdi Sharawi Doctor Ashraf Khasawneh Viral Replication Mechanisms: (Protein Synthesis) 1. Monocistronic Method: All human cells practice the monocistronic
More informationInfluenza viruses are classified as members of the family
Rewiring the RNAs of influenza virus to prevent reassortment Qinshan Gao a and Peter Palese a,b,1 Departments of a Microbiology and b Medicine, Mount Sinai School of Medicine, New York, NY 10029 Contributed
More informationAnimal hosts Natural host Laboratory animals Rabbits Mice Rats Hamsters Newborn or suckling rodents Animal models for viral pathogenesis 4 Growth of v
Principles of Virology Department of Molecular Genetics & Microbiology Univ ersity of Florida, Gainesv ille, FL 1 Outline Virus cultivation Assay of viruses Virus genetics 2 Virus isolation Evidence of
More informationhttp://www.ibs.upm.edu.my Challenges in controlling viral diseases of poultry Abdul Rahman Omar Institute of Bioscience Faculty of Veterinary Medicine Universiti Putra Malaysia aro@upm.edu.my Outline of
More informationBrief Definitive Report
Brief Definitive Report HEMAGGLUTININ-SPECIFIC CYTOTOXIC T-CELL RESPONSE DURING INFLUENZA INFECTION BY FRANCIS A. ENNIS, W. JOHN MARTIN, ANY MARTHA W. VERBONITZ (From the Department of Health, Education
More informationUnidirectional RNA polymerase I polymerase II transcription system for the generation of influenza A virus from eight plasmids
Journal of General Virology (2000), 81, 2843 2847. Printed in Great Britain... SHORT COMMUNICATION Unidirectional RNA polymerase I polymerase II transcription system for the generation of influenza A virus
More informationNature Medicine: doi: /nm.4322
1 2 3 4 5 6 7 8 9 10 11 Supplementary Figure 1. Predicted RNA structure of 3 UTR and sequence alignment of deleted nucleotides. (a) Predicted RNA secondary structure of ZIKV 3 UTR. The stem-loop structure
More informationReceived 17 December 2003 /Accepted 26 February 2004
JOURNAL OF VIROLOGY, July 2004, p. 6927 6937 Vol. 78, No. 13 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.13.6927 6937.2004 The Two Major Human Metapneumovirus Genetic Lineages Are Highly Related Antigenically,
More informationSupplementary Figure 1 Weight and body temperature of ferrets inoculated with
Supplementary Figure 1 Weight and body temperature of ferrets inoculated with A/Anhui/1/2013 (H7N9) influenza virus. (a) Body temperature and (b) weight change of ferrets after intranasal inoculation with
More informationTOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE
TOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE Peter Palese Icahn School of Medicine at Mount Sinai New York OPTIONS IX 8-26-16 ISIRV - Options IX for the Control of Influenza Peter Palese, PhD Professor
More informationCoronaviruses cause acute, mild upper respiratory infection (common cold).
Coronaviruses David A. J. Tyrrell Steven H. Myint GENERAL CONCEPTS Clinical Presentation Coronaviruses cause acute, mild upper respiratory infection (common cold). Structure Spherical or pleomorphic enveloped
More informationLive-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics
PERSPECTIVE SERIES The future of vaccine design Peter Palese and Adolfo García-Sastre, Series Editors Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of
More informationPrinciples of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
More informationRole of Individual Glycoproteins of Human Parainfluenza Virus Type 3 in the Induction of a Protective Immune Response
JOURNAL OF VIROLOGY, Mar. 1988, p. 783-787 0022-538X/88/030783-05$02.00/0 Copyright 1988, American Society for Microbiology Vol. 62, No. 3 Role of Individual Glycoproteins of Human Parainfluenza Virus
More informationRECOMBINANT VACCINES Live or Killed
Antigens and Vaccines Molecular biology drives Innovation Antigen Gene of Interest Recombination RECOMBINANT VACCINES Live or Killed Antigens and Vaccines Molecular biology drives Innovation Antigen Gene
More informationCharacterization of a Recombinant Newcastle Disease Virus Vaccine Strain
CLINICAL AND VACCINE IMMUNOLOGY, Oct. 2008, p. 1572 1579 Vol. 15, No. 10 1556-6811/08/$08.00 0 doi:10.1128/cvi.00156-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Characterization
More informationHemagglutinin Mutants of Swine Influenza Virus Differing in
INFECTION AND IMMUNITY, Oct. 1979, p. 197-201 0019-9567/79/10-0197/05$02.00/0 Vol. 26, No. 1 Hemagglutinin Mutants of Swine Influenza Virus Differing in Replication Characteristics in Their Natural Host
More informationDefective Interfering Particles of Respiratory Syncytial Virus
INFECTION AND IMMUNITY, Aug. 1982, p. 439-444 0019-9567/82/080439-06$02.00/0 Vol. 37, No. 2 Defective Interfering Particles of Respiratory Syncytial Virus MARY W. TREUHAFTl* AND MARC 0. BEEM2 Marshfield
More informationNOTES CONTAMINATION OF CYNOMOLGUS MONKEY KIDNEY CELL CULTURES BY HEMAGGLUTINATING SIMIAN VIRUS (SV 5)
Japan. J. Med. Sci. Biol., 18, 151-156, 1965 NOTES CONTAMINATION OF CYNOMOLGUS MONKEY KIDNEY CELL CULTURES BY HEMAGGLUTINATING SIMIAN VIRUS (SV 5) Since the extensive use of cynomolgus monkey kidney cell
More informationAvian Influenza Virus H7N9. Dr. Di Liu Network Information Center Institute of Microbiology Chinese Academy of Sciences
Avian Influenza Virus H7N9 Dr. Di Liu Network Information Center Institute of Microbiology Chinese Academy of Sciences Avian Influenza Virus RNA virus, Orthomyxoviruses Influenza A virus Eight Gene segments
More informationProduction of Interferon Alpha by Dengue Virus-infected Human Monocytes
J. gen. Virol. (1988), 69, 445-449. Printed in Great Britain 445 Key words: IFN-ct/dengue virus/monocytes Production of Interferon Alpha by Dengue Virus-infected Human Monocytes By ICHIRO KURANE AND FRANCIS
More informationFigure S1. Schematic presentation of genomic replication of idsiv after transfection and infection. After transfection of idsiv plasmid DNA into 293T
Figure S1. Schematic presentation of genomic replication of idsiv after transfection and infection. After transfection of idsiv plasmid DNA into 293T cells, the RNA genomes with all modifications are generated
More informationRecombinant Protein Expression Retroviral system
Recombinant Protein Expression Retroviral system Viruses Contains genome DNA or RNA Genome encased in a protein coat or capsid. Some viruses have membrane covering protein coat enveloped virus Ø Essential
More informationHepatitis B Antiviral Drug Development Multi-Marker Screening Assay
Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Background ImQuest BioSciences has developed and qualified a single-plate method to expedite the screening of antiviral agents against
More informationMeasles is a chilhood disease caused
Paediatrica Indonesiana VOLUME 48 May 2008 NUMBER 3 Original Article Antigenic differences between wildtype measles viruses and vaccine viruses in Indonesia Made Setiawan 1, Agus Sjahrurachman 2, Fera
More informationImmunogenicity of Avian Influenza H7N9 Virus in Birds
Immunogenicity of Avian Influenza H7N9 Virus in Birds Identification of Viral Epitopes Recognized by the Immune System Following Vaccination and Challenge Darrell R. Kapczynski US DEPARTMENT OF AGRICULTURE,
More informationPlaque Assay of Sendai Virus in Monolayers of a Clonal Line
JOURNAL OF CUNICAL MICROBIOLOGY, Feb. 1976. p. 91-95 Copyright 1976 American Society for Microbiology Vol. 3, No. 2 Printed in U.SA. Plaque Assay of Sendai Virus in Monolayers of a Clonal Line of Porcine
More informationHemagglutinin-stalk specific antibodies: How to induce them and how to measure them
Immunodominant head domain Stalk domain Hemagglutinin-stalk specific antibodies: How to induce them and how to measure them Florian Krammer Icahn School of Medicine at Mount Sinai May 5 th 2014 2 nd WHO
More informationFormation of an Infectious Virus-Antibody Complex with Rous
JOURNAL OF VIROLOGY, Mar. 1976, p. 163-167 Copyright 1976 American Society for Microbiology Vol. 17, No. 3 Printed in U.S.A. Formation of an Infectious Virus-Antibody Complex with Rous Sarcoma Virus and
More informationSupplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR
Supplemental Materials and Methods Plasmids and viruses To generate pseudotyped viruses, the previously described recombinant plasmids pnl4-3-δnef-gfp or pnl4-3-δ6-drgfp and a vector expressing HIV-1 X4
More informationIdentification of Mutation(s) in. Associated with Neutralization Resistance. Miah Blomquist
Identification of Mutation(s) in the HIV 1 gp41 Subunit Associated with Neutralization Resistance Miah Blomquist What is HIV 1? HIV-1 is an epidemic that affects over 34 million people worldwide. HIV-1
More informationFusion properties of cells constitutively expressing human parainfluenza virus type 4A haemagglutinin-neuraminidase and fusion glycoproteins
Journal of General Virology (1994), 75, 3517 3523. Printed in Great Britain 3517 Fusion properties of cells constitutively expressing human parainfluenza virus type 4A haemagglutinin-neuraminidase and
More informationUNIVERSAL INFLUENZA VIRUS VACCINES Adolfo García Sastre. Icahn School of Medicine at Mount Sinai, New York
UNIVERSAL INFLUENZA VIRUS VACCINES Adolfo García Sastre Icahn School of Medicine at Mount Sinai, New York INFLUENZA VIRUSES PAx B EPIDEMIOLOGY OF HUMAN INFLUENZA VIRUSES A H1N1 H3N2 1968 H2N2 1957 H1N1
More informationHIV-1 Virus-like Particle Budding Assay Nathan H Vande Burgt, Luis J Cocka * and Paul Bates
HIV-1 Virus-like Particle Budding Assay Nathan H Vande Burgt, Luis J Cocka * and Paul Bates Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
More informationASEAN STANDARDS FOR ANIMAL VACCINES
Adopted at the 40 th AMAF 11 October 2018 Ha Noi, Viet Nam ASEAN Cooperation in Food, Agriculture and Forestry ASEAN STANDARDS FOR ANIMAL VACCINES Third Edition Li v e s t o c k Publication Series No.2A
More information